DAFTAR PUSATAKA

Abdulkareem IH (2013). Aetio-pathogenesis of breast cancer. Niger   Med J.54(6): 371–375.

Adamo B and Anders CK (2011). Stratifying triple-negative breast cancer: which definition(s) to use?. Breast Cancer Research 13:105.

Alco G, Bozdogan A, Selamoglu, Pilanci NK, Tuzlali S, Ordu C, Igdem S (2015). Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients.Oncol Lett. 9(3): 1046–1054

American Cancer Society, 2014. Breast Cancer. Atlanta: American Cancer Society.

Amirikia K, Mills P, Bush J, Newman L (2011). Higher Population-Based Incidence Rates of Triple-Negative Breast Cancer Among Young African American Women: Implications for Breast Cancer Screening Recommendations. Cancer. 2011 June 15; 117(12): 2747–2753.

Andres C and Carey L (2008). Understanding and Treating Triple-Negative Breast Cancer.Oncology 22(11): 1233–1243.

Arkhipov A, Shan Y, Kim ET, Dror RO, Eshaw D (2013). Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. Arkhipov *et al*. eLife 2: e00708.

Azambuja, Cardoso F, Castro GJr, Colozza M, Mano MS, Durbecq V, Sotiriou C(2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. British Journal of Cancer 96: 1504–1513.

Ball J, Dains JE, Flynn JA, Barry (2015). Breasts and axillae. Dalam: Ball Jane W, Dains Joyce E, Flynn John ,Solomon Barry S and Stewart Rosalyn.*Seidel's Guide to* PHYSICAL EXAMINATION. Philadelphia: Elsevier Inc

Beahm E, and Lang JE, 2013. Breast cancer: Diagnosis, therapy, and oncoplastic techniques. In (Nelligan PC) Plastic Surgery 3rd Ed. Philadelphia: Elsevier Saunders.

Bhargava R, Striebe J, Beriwal S, Flickinger J, Onisko A, Ahrendt G and Dabbs D (2009). Prevalence, Morphologic Features and Proliferation Indices of Breast Carcinoma Molecular Classes Using Immunohistochemical Surrogate Markers. Int J Clin Exp Pathol 2, 444-455

Boyle P (2012).Triple-negative breast cancer: Epidemiological considerations and recommendations.Annals of Oncology 23: vi7–vi12.

Boyd N, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA. (2007). Mammographic Density and the Risk and Detection of Breast Cancer.N Engl J Med 356: 227-36.

Bray F, McCarron P and Parkin DM (2004). The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 6: 229-239.

Britten A, Rossier C, Tarighta N, Ezra P, Bourgier (2013). Genomic classifications and radiotherapy for breast cancer. European Journal of Pharmacology 717: 67–70.

Cantley LC (2002). The phosphoinositide 3-kinase pathway. Science 296.

Cianfrocca M and Gradishar W (2009). New Molecular Classifications of Breast Cancer. CA CANCER J CLIN 59: 303–313.

Chang L, Grahama PH, Nia J, Haoa J, Buccia J, Cozzib PJ, Lia Y (2015). Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.Critical Reviews in Oncology/Hematology xxx:vxxx–xxx.

Changav Ai, Shashikal A, and Ramji A (2015).Epidermal Growth Factor Receptor Expression in Triple Negative and Nontriple Negative Breast Carcinomas. J lab physician 7 (2): 79-83

Chandran VI, Castori SE, Thejaswini, Vine VK ,and Ranson M (2015). HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer.Oncoscience.2(3): 207–224.

Chan M, Vieira R, Aune D, Bandera V, Greenwood C, McTiernan A, Rosenblatt N et al., (2014). Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studie. Annals of Oncology 00: 1–14

Cheang m, Martin M, Nielsen T, prat A , Voduc D, Rodriguez A, Ruiz H et al., (2015). Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. TheOncologist 2015;20:474–482

Chung A, Cui X, Audeh W, Giuliano A (2013).Current status of antie Human epidermal growth factor receptor 2 therapies: Predicting and overcoming herceptin resistance.Clinical Breast Cancer 13 (4): 223-32.

Colozza, Azambuja, Cardos, Sotiriou C, Larsimont D & Piccart (2005). Proliferative markers as prognostic and predictive tools in early breast cancer: Where are we now? Annals of Oncology 16: 1723–1739.

Cresti N, Lee J, Rourke E, Televantou D, Jamieson D, Verrill M, Boddy AV (2016). Geneticvariants in the HER2 gene: Influence on HER2

overexpression   and loss of heterozygosity in breast cancer. European   Journal of Cancer 55: 27-37.

Criscitiello C, Azim, Schouten, Linn & Sotiriou C (2012). Understanding the biology of triple-negative breast cancer.Annals of Oncology 23: vi13–vi18.

Cserni G, Vörös A, Karele IL, Bianchi S, Vezzosi V, Grabau D, Sapino A (2014).Distribution pattern of the Ki67 labelling index in breast cancer and its implications for choosing cut-off   values.   The Breast 23:   259-263.

Curtit E, Nerich V, Lauramansi, Chaigneau L, Cals L, Villanueva C, *et al.*, (2013). Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis. Oncologist 18: 667–74.

Culver JB, Hull J, Lahad EL, Daly M, dan Burke W, (2000). Breast Cancer Genetics- An Overview. Gene Clinics University of Washington, Seattle.

Devi U (2005). Basics of carcinogenesis. Health Administrator 17 (1): 16-24.

Denkert C, Budczies J, Minckwitz GV, Wienert Stephan, Loibl   Sibylle, Klauschen   Frederick (2015).Strategies for developing Ki67 as a   useful biomarker in breast   cancer. The Breast 24: S67-S72

Degos L, Linch CD, Lowenberg B (2005). Textbook of malignant hematology. Taylor   & Francis Medical Books: London and New York, pp: 617-1368.

Dey N,Williams C, Jones BL, De P (2015). A critical role for HER3 in HER2-amplified and non-amplified breast cancers: Function   of   a kinase-dead RTK.Am J Transl Res 7(4): 733-750

Dowsett M, Nielsen T,   Hern R, Bartlett J,   Coombes CR, Cuzick J, Matthew E (2011). Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 103: 1656–1664.

Dumitrescu RG And Cotarla I (2005). Understanding breast cancer risk-where do you standin 2005?. J. Cell. Mol. Med.9 (1),pp. 208-221

Eisenberg Ana LA, Pinto IV and Koifman S (2013). Triple-Negative breast cancer in brazilian women without metastasis to axillary   lymph nodes: Ten-Year survival and prognostic factors. British Journal of Medicine &Medical Research 3(4): 880-896.

Engels CC, Kiderlen M, Bastiaannet E, Mooyaart AL, Vlierberghe R, Smit *et al.,* (2015).The clinical prognostic value of molecular intrinsic tumor subtypes in older breast cancer patients: A Focus study analysis. Molecular Oncology 30: 1-7.

EngstrømM, Opdahl S, Hagen I, Romundstad R, Akslen A, Haugen A, Vatten J, Bofin M (2013). Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 140:463–473

English DP, Roque DM., and Santin AD (2014). HER2 expression beyond breast cancer: Therapeutic implications for gynecologic malignancies. Mol Diagn The 17(2): 85–99.

Moloney E (2014).Ageing and Cancer: A complex relationship.Cancer Council Australia

Elzawahry H, Saber MM, Mokhtar NM, Zeeneldin AA, Ismail YM, Alieldin NH (2013). Role of Ki67 in predicting resistance to adjuvant tamoxifen in postmenopausal breast cancer patients. Journal of the Egyptian National Cancer Institute 25: 181–191.

Elkablawy M, Albasri A, Mohammed R, Hussainy A, Nouh M, Alhujaily A (2016).Ki67 expression in breast cancer:Correlation with prognostic markers and clinicopathological parameters in Saudi patients. Saudi Med J; 37 (2)

Eroles P, Ana B, Fidalgo AP, Lluch A (2012). Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treatment Reviews 38: 698–707.

Ermiah E, Buhmeida A, Abdalla F, Khaled B, Salem N, Pyrhönen S and Collan Y (2012). Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in Libya. Journal Of Cancer 3: 421-431.

Esposito A, Criscitiello C and Curigliano G (2015). Highlights from The 14Th St Gallen International Breast Cancer Conference 2015 in Vienna:Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer.eCancer 2015, 9: 518

Francken AB, Schouten PC, Bleiker E, Linn S, Rutgers E (2013). Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies. The Breast 22: 561-568.

Falck AK, Bendahl PO, Chebil G, Olsson H, Ferno M and Ryden L (2013). Biomarker expression and St Gallen molecular subtype   classification   in primary tumours, synchronous lymph node metastases and   asynchronous relapses in   primary breast cancer patients with 10 years'follow-up.Breast Cancer Res Treat ;140:93–104.

Fasching PA, Heusinger K, Haeberle L, Niklos M, Hein A,Bayer CM, Rauh C (2011). Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer 11: 486.

Feeley LP, Mulligan AM, Pinnaduwage D, Bull SB and Andrulis IL (2014). Distinguishing luminal breast cancer subtypes by Ki67,progesterone receptor or TP53 status provides prognostic information. Modern Pathology 27: 554–561

Fiszman GL And Jasnis MA (2011). Molecular mechanisms of trastuzumab resistance in HER2 Overexpressing breast cancer. International Journal of Breast Cancer: 11 pages.

Fruman DA And Romme C (2014). PI3K and Cancer: Lessons, challenges and opportunities. Nat Rev Drug Discov 13(2): 140-156.

Francken AB, Schouten P, Bleiker E, Linn S, Rutgers E (2013). Breast cancer in women at high risk: The role of rapid genetic testing for BRCA1 and -2 mutations and the consequences for treatment strategies.The Breast 22: 561-568

Fu SW, Lee W, Coffey C, Lean A, Wu X, Tan X, Man Y *et al.*, (2016). miRNAs as potential biomarkers in early breast cancer following detectition mammography.Cell Biosci 6: 6.

Galukande M, Wabinga H, Mirembe F, Karamagi C, Asea A (2014).Molecular breast cancer subtypes prevalence in an indigenous Sub Saharan African

Population. Pan African Medical Journal. 2014; 17:249

Gasco M, Shami S and Crook T (2002).The p53 pathway in breast cancer. *Breast Cancer Res* 2002, 4:70-76

Gajria D and Sarat C (2011). HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 11(2): 263–275.

Germain D (2011). Estrogen Carcinogenesis in Breast Cancer. Endocrinol Metab Clin N Am 40: 473–484

GiulianoM, Meghana VT, and Rachel S (2013).Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: Molecular basis and clinical implications. Breast Care (Basel) 8(4): 256–262.

Gleadle J (2007). At a Glance: Anamnesis dan pemeriksaan fisik. Jakarta: erlangga

Green AR, Barros F, Fatah TA, Moseley P, Nolan C, Durham A, Rakha E*et al.,* (2014). HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat145: 33–44.

Gretchen G, Burke A, Anderson W (2010). Epidemiology of triple negative breast cancer.Breast Dis 32 (0): 5–24.

Haward R, Goldacre M, Mason A, Wilkinson E, dan Amess M (1999). Health Outcome Indicators: Breast Cancer. Report of a working group to the Department of Health. Oxford: National Centre for Health Outcomes Development.

Harbeck N, Thomssen C, Gnant Michael (2013).St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion. Breast Care 8:102–109

Hanahan D and Weinberg RA (2000). The Hallmarks of Cancer. Cell, 100: 57–70

Haroon S, Hashmi AA, Khurshid A, Kanpurwala Muhammad A,Mujtuba S, Malik B, Faridi N (2013). Ki67 Index in Breast Cancer: Correlation with Other Prognostic. Asian Pac J Cancer Prev 14(7):4353-8.

Harari D and Yarden Y (2000).Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.Oncogene 19: 6102-6114.

Hassan I, Tarcisia T, Agnestina, Tarcisia S, and Nasar M *et al.,* (2013). Ki-67 marker useful for classification of malignant invasive ductal breast cancer. Universa Medicina 32 (3): 179-86.

Hanrahan A, Iyer G, and Solit DB (2014). Intracellular signaling. Dalam: Nierder Huberjhon E, Armitage O James MD, Doroshow H James MD, Kastan Michael MD, Tepper E Joel MD. Abeloff's Clinical Oncology. Philadelphi: Elsevier Inc.

Hemming BA And Restuccia D (2012). PI3K-PKB/Akt Pathway.Cold Spring Harb Perspect Biol 4: a011189.

He J, Yang J , Chen W, Wu H,Yuan Z, Wang K, Li G(2015). Molecular features of Triple Negative breast cancer: Microarray evidence and further integrated analysis. PLoS ONE 10(6): e0129842.

Hirata BK, Oda JM, Guembarovski RL, Ariza CB, Oliveira C and Watanabe M (2014). Molecular Markers for Breast Cancer: Prediction on Tumor Behavior:12pages

Howland N, Driver T, Sedrak M, Wen X, Dong W, Hatch S, Eltorky M (2013). Lymph node involvement in immunohistochemistry-based molecular

classifications of breast cancer. Journal Of Surgica Research 185:697-703.

Hosseini S, Shahbaziyan H, Razmjoo S and Jasemizade N(2015). Evaluation the Correlation between Ki67 and 5 Years Disease Free Survival of Breast Cancer Patients. Biosciences biotechnology research asia: **12**(3), 2221-2225.

Huo D, Ikpatt F, Khramtsov A, Dangou J, Nanda R, Dignam J, Zhang B (2009). Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer. J Clin Oncol 27:4515-4521.

IARC (2013). Latest world cancer statistics Global cancer burden rises to 14.1 million new cases in 2012: Marked increase in breast cancers must be addressed. https : //www.iarc. fr/en/media-centre/pr/2013/pdfs/pr223_E.pdf - Diakses Februari 2016.

Inic Z, Zegarac M, Inic M, Markovic I, Kozomara Z, Djurisic I, *et al*., (2014). Difference between Luminal A and Luminal B Subtypes According to Ki-67,Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clinical Medicine Insights: Oncology 8; 107-11.

Inwald EC, Klinkhamm SM, Hofstädter f, Zeman, Koller, Gerstenhauer , *et al.,* (2013). Ki-67 is a prognostic parameter in breast cancer patients: Results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139: 539–552.

Ingolf B, Russalina M, Simona M, Julia R, Gilda S, Bohle RM, Andrea, Hasenfus (2014). Can Ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy? BioMed Research International.

Irvin W and Carey LA. (2008). What is triple-negative breast cancer?. European Journal of Cancer 4 4: 2 7 9 9 –2 8 0 5

Iqbal N and Iqbal N (2014). Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int; 1-9.

Jemal A, Center MM, DeSantis C, Ward EM (2010). Global patterns of cancer incidens and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8): 1893-907.

Jiao Q, Wu A, Shao G, Peng H,Wang M, Liu P (2014).The latest progress in research on triple negative breast cancer (TNBC): risk factors,possible therapeutic targets and prognostic markers.J Thorac Dis.6(9):1329-35.

Jeon Y, Kang S, Park M , LimW, Cho S and Suh Y (2015).Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival. BMC Cancer 15:865

Jiang N,Saba NF, and Chen ZG (2012).Advances in targeting HER3 as an anticancer therapy.Chemotherapy Research and Practice. p: 9

Jonat W dan Arnold N (2011). Is the Ki-67 labelling index ready for clinical use?. Ann Oncol 22 (3): 500-502.

Joensuu K, Leidenius M, Kero M,   Andersson LC,   Horwitz   KB and Heikkilä P (2013). ER, PR, HER2, Ki-67 and K5 in arly and Late Relapsing Breast ancer-Reduced K5 xpression in Metastases. Breast Cancer: Basic and Clinical Research 7: 23–34.

Karakas B, Bachman KE and Park BH, (2006). Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer 94: 455 – 459.

Keam B, Im S, Lee KH, Han SW, Do Y, Kim JH , Lee SH (2011). Ki-67 can be used for further classification of riple negative breast cancer into two subtypes with different response and prognosis Keam *et al.,* Breast Cancer Research 13: R22.

Khambri D (2015). Hubungan ekspresi androgen receptor dengan faktor prognostik   karsinoma payudara di sumatera barat. Program Pascasarjana S3 Ilmu Kedokteran Universitas Andalas. Disertasi.

Kementerian Kesehatan RI, (2015). INFODATIN Pusat Data dan Informasi. Jakarta:Kemenkes RI.

Kristiina J, Leidenius M, Kero M, Andersson LC, Horwitz KB and Heikkilä P (2013). ER, PR, HR2, Ki-67 and K5 in arly and late relapsing breast cancer—reduced K5 xpression in metastases. *Breast Cancer: Basic and Clinical Research* 7: 23–34.

Kim H, Cho J, Kwon and Kan SH (2015). Biologic subtype is a more important prognostic factor than nodal   involvement in patients with stages I and II breast carcinoma. Ann Surg Treat Res 90:1-9.

Kilickap S, Kaya Y, Yucel B, Tuncer E, Babacan NA, Elagoz S (2014). Higher Ki67 expression is associates with unfavorable prognostic factors and shorter survivalin breast cancer. APJCP 15(3): 13-81.

Klintman M, Bendah P, Grabau D, Lo¨vgren K, Malmstro¨m P and Ma°rten P (2010). The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Modern Pathology (2010) 23, 251–259.

Kontzoglou K, Palla V, Karaolanis G, Karaiskos I, Alexio Konstantoudakis K(2013).Correlation between Ki67 and breast cancer prognosis. Oncology 84: 219–225.

Komen SG (2014). What is Breast Cancer.https://ww5.komen.org/uploaded Files/Komen/Content/About_Breast_Cancer/Tools_and_Resources/Fact_She ets_and_Breast_Self_Awareness_Cards/What%20is%20Breast%20Cancer.pf diakses pada pada 13 Maret 2016.

Komatsu M, Yoshimaru T, Matsuo T, Kiyotani K, Miyoshi Y, Tanahashi T, Rokutan K (2012). Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis 42 (2): 478-506.

Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P and Witkiewicz AK (2015). RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle.14 (1): 109–122.

Kutomi G, Tousei O, Yasuyo S, Hidekazu K, Hiroaki S, Tomoko T, Fukino S *et al.,* (2012). Clinicopathological characteristics of basal type breast cancer in Triple-Negative Breast Cancer. Journal of Cancer Therapy 3: 836-840

Kumar V, Cotran R, Robbin S (2007). Buku ajar patologi. Jakarta: Penerbit Buku Kedokteran EGC.

Lawrence and Lawrence R (2014). The Breast and the Physiology of Lactation. Dalam: Creasy Robert , Resnik Robert , Iams Jay, ockwood Charles J, Moore Thomas R and Greene Michael .Creasy and Resnik's Maternal-Fetal Medicine, principles and practice. Philadelphia: Elsevier Inc

Lam SW, Jimenez CR , Boven (2014). Breast cancer classification by proteomic technologies: Current state of knowledge. Cancer Treatment Reviews 40: 129–138.

Lenggogeni P (2011). "Faktor-faktor yang berhubungan dengan deteksi tindakan deteksi dini kanker payudara melalui pemeriksaan payudara sendiri oleh mahasiswi jalur A program studi ilmu kesehatan masyarakat fakultas kedokteran unand padang tahun 2011". Dalam (Bagian Rekam Medik RSUP dr. M. Djamil Padang) Statistik Kanker di RSUP dr. M. Djamil Padang 2009-2011.Padang: Bagian Rekam Medik RSUP Dr. M. Djamil Padang; Skripsi FKM Unand.

Lehmann B, Bauer J, Chen X, Sanders ME, Chakravarthy B, Shyr Y and Pietenpol JA. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 121 (7): 2750–2767.

Li H, Han X, Liu Y, Liu G and Dong G (2015). Ki67 as a predictor of poor

prognosis in patients with triple-negative breast cancer. Oncology   Letters 9(1): 149–152.

Peng L, Xu T, Long T, Zuo H (2016). Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis. Med Sci Monit   22: 1939-1945.

Pillai S, Tay A, Nair S and Leong C (2012). Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clinical Pathology 2012, 12:18

LoPiccolo J, Blumenthal G, Bernstein W and Dennis   PA (2008). Targeting the PI3K/Akt/mTOR pathway: Effective combinations   and   clinical considerations. Drug Resist Updat. 11(1-2): 32–50.

Lønning and Knappskog (2013). Mapping genetic alterations causing chemoresistance in cancer: Identifying the roads by tracking the drivers Open.*Oncogene* 32: 5315–5330.

Madani S, Payandeh M, Sadeghi M, Motamed H, Sadeghi E (2016).The correlation   between Ki-67 with other prognostic factors in breast cancer: A study in Iranian patients. Indian Journal Of Medicaland Pediactric Oncology: 37:95 - 99.

Mirtavoos-Mahyari H, Khosravi A, Esfahani-Monfared Z (2014).Human Epidermal Growth Factor Receptor 2 and Estrogen Receptor Status in Respect to Tumor   Characteristics in Non-Metastatic Breast Cancer. Tanaffos 2014; 13(1): 26-34

Ma CX (2015). The PI3K Pathway as a Therapeutic Target in Breast Cancer.The American Journal of Hematologi/Oncology11:3.

Masionneuve P, Disalvatore D, Rotmensz N, Curiglano G, Colleoni M, Dellapasqua S, *et   al.,* (2014). Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res;   16:R65.

Madjar H (2010). Role of Breast Ultrasound for the Detection and Differentiation   of Breast Lesions. Breast Care 5: 109–114.

Manucha V, Zhang X, Thomas RM (2014) . The satisfactory reproducibility of the Ki-67 index in breast carcinoma, and it's correlation with the recurrence score.Philadelphia 3: 310-314

McKee T, and McKee JR, (2013). Biochemistry in Perspective: Carcinogenesis. Dalam (McKee T, McKee JR) Biochemistry: The Molecular Basis of Life Updated 5th Ed. Oxford University Press.

Mizuno Y, Fuchikami H, Natori T, Takeds N, Inoue Y,Yamada J *et al.,* (2014). Standardized assessment of Ki-67 in breast cancer patients   using   virtual

slides and an automated analyzerin comparison to central/local pathological assessments.Journal of Cancer Therapy 5: 141-146.

Moasser MM (2007).The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis.Oncogene 26 (45): 6469–6487.

Mohammed Z, McMillan DC, Edward J, Mallon E, Doughty JC, Orange C and Going JJ (2013). The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. Mohammed *et al*. BMC Clinical Pathology 13: 31.

Moloney E (2014). Ageing and Cancer: A complex relationship. Cancer Council Australia 2014 Essay Competition

Mrklic´I, Pogorelic Z, apkunc V, Tomi S (2013). Expression of androgen receptors in triple negative breast carcinomas.Acta Histochemica 115: 344– 348.

Nahta R (2012). Molecular mechanisms of trastuzumab-based treatment in HER2-Overexpressing breast cancer.International Scholarly Research Network: 16 pages.

Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y and Arima N (2010). Ki-67 as a prognostic marker according to breast cancer subtype and a predictor   of recurrence time   in primary breast cancer. Exp Ther Med 1: 747–754.Parkin Donald M(2005).GlobalCancer Statistics, 2002.*Oncogene* 23: 6329–6340.

Niikura N, Masuda S, Kumaki N, Xiaoyan T, Terada M, Terao M, Iwamoto T *et al.,*(2014). Prognostic Significance of the Ki67 Scoring Categories in Breast Cancer Subgroups.Clinical Breast Cancer 14: 323-29

Nikhra P, Patel P, Taviad D and Chaudhary S (2014).   Study of ER (Estrogen Receptor), PR (Progesterone Receptor) & HER-2/NEU (Human Epidermal Growth Factor Receptor) expression by immunohistochemistry in breast carcinoma.ISSN: 2229-3809.

Ovcaricek T, Frkovic S,Matos E, Mozina B, Borstnar B (2010). Triple negative breast cancer – prognostic factors and survival. Radiol Oncol 2011; 45(1): 46-52.

Parthasarathi K(2015). Ki-67: a review of utility in breast cancer. Australian Medical Student Journal 6: 102-104.

Parise CA and Caggiano V (2014). Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to Tumor Grade and Immunohistochemical Biomarkers. Journal of Cancer Epidemiology: 2014, p: 11 pages.

Pal SK, Childs B, and Pegram M (2012).Triple negative breast cancer: unmet

medical needs.Breast Cancer Res Treat 125(3): 627–636.

Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, Arra C (2015). Triple negative breast cancer: Looking for the missing link between biology and treatments. Oncotarget. 6(29): 26560–26574.Pass Hellen A. (2011). The breast.

Parkin DM (2004).International variation.*Oncogene* (2004) 23, 6329–6340.

Pherson, Steel , and Dixon JM (2000).Breast cancer—epidemiology, risk factors, and genetics.BMJ 321(7261): 624–628.

Podoa F, Buydensb L, Deganic H, Hilhorstd R, Klippe E, Gribbestadf I, Huffelg E *et al.,* (2010). Triple-negative breast cancer: Present challenges and new perspectives. Mo l e c u l a r Onc o l o g y : 209 e2 2 9

Prat A, Carey L, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS (2014). Molecular features and survival outcomes of the intrinsic subtypes within Her2-Positive breast cancer.J Natl Cancer Inst.106(8): dju152

Ribelles N, Villa LP, Jerez JM, Pajares B, Vicioso L, Jimenez B, Luque V (2013). Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index. Ribelles et al. Breast Cancer Research15: R98

Sarode V, Han J, Morris D, Peng Y, and Rao R (2011). A Comparative Analysis of Biomarker Expression and Molecular Subtypes of Pure Ductal Carcinoma In Situ and Invasive Breast Carcinoma by Image Analysis: Relationship of the Subtypes with Histologic Grade,Ki67, p53 Overexpression, and DNA Ploidy. International Journal of Breast Cancer.2011: 7

Samuels Y and Waldman T(2010). Oncogenic Mutations of PIK3CA in Human Cancers. Curr Top Microbiol Immunol. 347: 21–41.

Schmidt C (2010). How Do You Tell Whether a Breast Cancer is HER2 Positive? Ongoing Studies Keep Debate in High Gear. *JNCI J Natl Cancer Inst* 103(2).

Seo SH, Choi SH, Choi SH, Choi KY, Um YJ, Choi I, Shin CY *et al.,* (2011). Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-B signaling in HER2-overexpressing breast cancer cells. Anticancer Research 31: 3301-3314.

Shervin K and Homaee F(2015). Ki-67 protein: A proliferation index in breast cancer. Rev Clin Med. 2 (4): 205-208..

Shui R, Yu B, Bi R, Yang F, Yang W(2015).An Interobserver Reproducibility Analysis of Ki67 Visual Assessment in Breast Cancer. PLoS ONE 10 (5): e0125131.

Shokouh TZ, Ezatollah A and Barand P (2015). Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes. Oncol Lett. 2015 Jan; 9(1): 149–152.

Singh M and Jangra B (2013). Association between body mass index and risk of breast cancer among females of north India. South Asian Journal of Cancer 2(3):121-125

Skjulsvik AJ, Mørk JN, Morten, Torp SH (2014). Ki-67/MIB-1 immunostaining in a cohort of human gliomas. Int J Clin Exp Pathol 7 (12):8905-8910.

Smith RA, Duffy SW, and Tabar L(2012). Breast Cancer Screening: The Evolving Evidence. Oncol (Huntingt); 26(5):471-5, 479-81, 485-6.

Song Y, ShinS, Cho J, Park M, Yoon J, Jegal Y (2011). The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer. J Breast Cancer; 14(3): 198-203

Sood N and Nigam J (2014). Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer. Pathology Research International 2014 : 6

Stahl D, Columbus K and Baggish M (2016).The Breast. Dalam: Baggish Michael S. MD, FACOG and Karram Mickey M. MD.Atlas of Pelvic Anatomy and Gynecologic Surgery. Philadelphia: Elsevier Inc

Suenaga A, Takada N, Hatakeyama M, Ichikawa M, Yu X, Tomii K, Okimoto N *et al.*, (2005). Novel mechanism of interaction of p85 subunit of phosphatidylinositol 3-Kinase and ErbB3 Receptor-derived Phosphotyrosyl Peptides. The Journal Of Biological Chemistry 280 (2), pp: 1321–1326.

Sun J, Chen C, Wei W, Zheng H, Yuan J, Tu Y, Yao F (2015). Associations and indications of Ki67 expression with cliniopathological parameters and molecular subtypes in invasive breast cancer: A population-based study. Oncology Letter10: 1741-1748.

SuY, Zheng Y, Zheng W, Gu K, Chen Z, Li G, Cai Q, Lu W, Shu O (2011). Distinct distribution and prognostic significance of molecular subtypes of breast cancer in Chinese women: a population-based cohort study. BMC Cancer 11:292

Thiygarajan M, Navrathan N, Mohanapriya T, Kumar N, Singh B (2015). Correlation between estrogen receptor, progesterone receptor, HER-2/neu status and other prognostic factors in carcinoma breast in Indian Population. Thiygarajan M et al. IntS urg J. 2015 Nov; 2(4):515-522

Tai W, Mahato R, and Cheng K (2010). The role of HER2 in cancer therapy and targeted drug delivery. Control Release. 146(3): 264–275. Tan Qi-Xing, Qin Qing-Hong, Yan Wei-Ping, Mo Qin-Guo, Wei Chang-Yuan (2014). Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol 7 (10): 6862-6870.

Takahashi R, Toh U, Iwakuma N, Mishima M, Fujii T, Takenaka M, Koura K *et al.,* (2013). Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy. Experimental And Therapeutic Medicine 6: 1089-1095,

Tamimi D, Shawarby M, Ahmed A, Hassan K and Adaini A (2010). Protein expression profile and prevalence pattern of the molecular classes of breast cancer - a Saudi population based study. *BMC Cancer* , **10**:22.

Telli M, Chang E, Kurian A, Keegan T, McClure L, Lichtensztajn D (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. *Breast Cancer Res Treat*. 2011 June ; 127(2): 471–478.

Torre L, Bray F, Siegel R, Ferlay J, Tieulent J, Lortet dan Jemal A(2015). Global cancer statistics. A Cancer Journal For Clinicians 65: 87-108.

Tomao F, Papa A, Zaccarelli E,Rossi L, Caruso D, Minozzi M, Vici P (2015).Triple-negative breast cancer: New perspectives for targeted therapies.Onco Targets Ther.8: 177–193.

Trihia H, Murray S, Price K, Gelber R, Golouh R, Goldhirsch A, Coates A (2003). Ki-67 expression in breast carcinoma: Its association with grading systems,clinical parameters, and other prognostic factors—A Surrogate Marker?. Cancer 97 (5).

Uripi V (2002). Menu Untuk Penderita Kanker.Jakarta: Puspa Swara.

Vadlakonda L, Dash A, Pasupuleti M, Kumar KA and Reddanna P (2013).The paradox of Akt-mTOR interactions. Front Oncol 3: 165.

Vadlakonda L, Pasupuleti M and Reddanna P (2013). Role of PI3K-AKT-mTOR and Wnt signaling pathways in transition of G1-S phase of cell cycle in cancer cells. Front Oncol 3: 85.

Vasudevan K, Barbie D, Davies M, Rabinovsky R, Near KJ, Hennessy BT (2009). AKT-Independent signaling downstream of oncogenic *PIK3CA* mutations in human cancer. Cancer Cell 16 (1): 21–32.

Vives P, Sánchez, Cantalejo S, Ramo T, Martos, Ardanaz,Chirlaque *et al.,* (2013). Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.Gynecologic Oncology 130 : 609–614.

Viale G. (2012). The current state of breast cancer classification. Annals of Oncology 23: x207–x210.

Wang W, Wu J, Zhang P, Fei X, Zong Y, Chen X, Huang O *et al.,* (2016).Prognostic and predictive value of Ki-67 in triple-negative breast cancer. Oncotarget 7: 21

Weston A and Harris C (2003). Multistage Carcinogenesis. Dalam: Kufe Donald W ,Pollock Raphael E, Weichselbaum Ralph R, Bast Robert, Gansler Ted Holland James F,and Frei Emil. Holland-Frei Cancer Medicine, 6th edition. NCBI.

White M, Holman D, Boehm J, Peipins L, Grossman M, and Henley J (2014).Age and Cancer Risk:A Potentially Modifiable Relationship. *Am J Prev Med*. 2014 March ; 46(3 0 1): S7–15.

Wilks ST (2015). Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway. The Breast 24; 548-555.

Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC , *et al.,* (2015). Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α Expression in Invasive Ductal Breast Cancer Patients and Correlations with Prognosis. Asian Pac J Cancer Prev, 16: (2): 823-829.

Yerushalmi R, Wood R, Ravdin PM, Hayes MM, Gelmon KA (2010). Ki67 in breast cancer: prognostic and predictive potential.Lancet Oncol 11: 174–83.

Yersal O and Barutca S (2014). Biological subtypes of breast cancer: Prognostic and therapeutic implications.World J Clin Oncol; 5(3): 412-424.

Yulianti H, Hernowo BS (2015). Hubungan antara Imunoekspresi Ki67 dan Risiko Agresivitas Tumor pada Gastrointestinal Stromal Tumor. MKB, 47 (4).

Yue W, Yager JD , Ji-Ping W, Eldon RJ, Santen R (2013).Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis.Steroids 78 (2013) 161–170

Zhang L, Fang C, Xu X, Li A, Cai Q, and Long X (2015). Androgen receptor, EGFR, and BRCA1 as biomarkers in Triple-Negative breast cancer: A meta-analysis. Biomed Res Int. 2015: 357485.

Zhong F, Bi R, Yu1 B, Yang F, Yang W, Shui R(2016).A comparison of visual assessment and automated digital image analysis of Ki67 labeling index in breast   cancer. PLoS ONE 11 (2): e0150505.